| 摘要 |
<p>The invention provides a method of treating a human suffering from the Syndrome of Type 2 Diabetes by administering, by a pharmaceutically effective mode, a drug composition having an opioidergic agent including opiates having µ-agonist activity, opiates having kappa antagonist activity or a combination thereof and an insulin secretagogue. The opioidergic agent is a compound selected from the group consisting of dihydromorphine, morphine, hydromorphine, methadone, fentanyl, sufentanyl, buprenorphine, demorphine, codeine, ethylmorphine, etonitazene, hydrocodone, levorphanol, norcodeine, normophine, (D - Ala2 - N - Me - Phe4 - Gly3 - o1) - Enkephalin (DAMGO) , oxycodone, loperamide, nor-binaltorphine, (-) - (1R, 5R, 9R) - 5, 9 - diethyl - 2 - (3 - furylmethyl) - 2 - hydroxy - 6 , 7 - benzomorphan (MR 2266) , a triethylenedioxy derivative of B - naltrexamine (TENTA) , and guanidylated naltrindole (GNTI) . The insulin secretagogue includes e.g sulphonylureas .</p> |
